TABLE OF CONTENTS

Intake/Assessment

- Policy/Procedure No. 00A — Initial Contact About COE Admission
  Intake Questionnaire
- Policy/Procedure No. 001 — Overview of COE’s Clinical Services
- Overview of Clinical Services
- Clinical Use of Extended-Release Injectable Naltrexone in the Treatment
  Of Opioid Use Disorder — A Brief Guide
- Policy/Procedure No. 002- Initial Contact Checklist
- Initial Patient Contact About Buprenorphine: Checklist
- Policy/Procedure No. 003 — Buprenorphine/Naloxone Maintenance Treatment for
  Patients
- Buprenorphine/Naloxone (Suboxone) Maintenance Treatment Information for Patients
- Policy/Procedure No. 004 — Injectable Naltrexone Maintenance Treatment Information
  for Patients
- Medication Guide — Vivitrol (naltrexone for extended-release injectable suspension)
- Policy/Procedure No. 005 — Intake History & Physical Examination
- Intake History & Physical Examination Form
- Policy/Procedure No. 005A — Assessment & Initial Treatment Plan
- Intake Assessment
- Initial Treatment Plan
- Policy/Procedure No. 006 — Psychiatric Evaluation Form
- Psychiatric Evaluation Form
- Policy/Procedure No. 007 — Worksheet for DSM 5 Opioid Use Disorder Diagnosis
- Opioid Use Disorder Diagnostic Criteria Checklist
- Policy/Procedure No. 008 — Intake Questionnaire for Treatment Planning for those
  Interested in Buprenorphine/Naloxone MAT
- Intake Questionnaire For Patient/Treatment — Planning Questions
- Policy/Procedure No. 009 — Patient Information: Buprenorphine/Naloxone Induction
  (Treatment Days 1 – 2)
- Buprenorphine/Naloxone Induction (Treatment Days 1 – 2)
- Policy/Procedure No. 010 – Treatment Agreement
- Injectable Naltrexone Treatment Agreement
• Buprenorphine/Naloxone Treatment Agreement
• Policy/Procedure No. 011 – Patient Consent for the Release of Confidential Information
• Patient Consent for The Release of Confidential Information
• Policy/Procedure No. 012 – Mini International Neuropsychiatric Interview, Version 5.0.0 (MINI)
• MINI International Neuropsychiatric Interview
• Policy/Procedure No. 013 – The Drug Abuse Screening Test (DAST)
• The Drug Abuse Screening Test
• Policy/Procedure No. 013A – Naloxone Education
• Opioid Overdose Prevention Toolkit
• Policy/Procedure No. 014 – The Alcohol Use Disorders Identification Tool (AUDIT)
• AUDIT

Induction

• Policy/Procedure No. 015 – Buprenorphine/Naloxone Induction
• Buprenorphine/Naloxone Induction
• Policy/Procedure No. 016 – Clinical Opiate Withdrawal Scale (COWS)
• Clinical Opiate Withdrawal Scale (COWS)
• Policy/Procedure No. 017 – Extended Release Injectable Naltrexone Medical Protocol and Procedures
• Extended Release Injectable Naltrexone Medical Protocol and Procedures

Follow-Up

• Policy/Procedure No. 018 – Patient Protocol for Follow-up Appointments
• Protocol for Follow-Up Appointments
• Policy/Procedure No. 019 – Progress Note Format for Physicians
• Progress Note Structure (Physicians)
• Policy/Procedure No. 020 – Progress Note Format for Case Managers
• Progress Note Structure (Case Managers)

Record Keeping/Accountability

• Policy/Procedure No. 021 – Buprenorphine/Naloxone Administration, Documentation and Storage Requirements
• Policy/Procedure No. 022 – Drug Accountability Record
• Drug Accountability Record
• Policy/Procedure No. 023 – Buprenorphine Dose Log
• Buprenorphine Dose Log
Buprenorphine Information

- Policy/Procedure No. 024 – Buprenorphine Information for Patients
- Buprenorphine/Naloxone Maintenance Treatment Information for Patient
- Buprenorphine/Naloxone Induction (Treatment Days 1 – 2)
- Policy/Procedure No. 025 – Buprenorphine Information for Family Members
- Buprenorphine/Naloxone Maintenance Treatment Information for Opioid Dependence
- Policy/Procedure No. 026 – More Information about Medication Assisted Treatment

Injectable Naltrexone Information for Patients

- Policy/Procedure No. 024A – Injectable Naltrexone Information for Patients
- Vivitrol (Naltrexone for Extended-Release Injectable Suspension) Medication Guide
- Policy/Procedure No. 024B – Injectable Naltrexone Information for Clinical Staff
- Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide

Ongoing Treatment

- Policy/Procedure No. 027 – Toxicology Screening
- Policy/Procedure No. 027A – Pill Counts
- Pill Count
- Policy/Procedure No. 028 – Billing for Services
- Clinical Services Recording Form
- Policy/Procedure No. 029 – Clinical Supervision
- Policy/Procedure No. 030 – Treatment Planning
- Treatment Plan
- Policy/Procedure No. 030A – Addressing Relapse
- Approaches to Relapse
- Policy/Procedure No. 031 – Discharge Planning
- Policy/Procedure No. 032 – Orientation Materials for Clients
- Welcome Sheet
- Methadone Information Sheet
- Buprenorphine Information Sheet
- Naltrexone Information Sheet
- Injectable Naltrexone Treatment Agreement
- Buprenorphine/Naloxone Treatment Agreement
- Buprenorphine/Naloxone Induction (Treatment Days 1 – 2)
- VIVITROL Medication Guide
- Buprenorphine/Naloxone Maintenance Treatment Information for Patient
- Buprenorphine/Naloxone Maintenance Treatment Information for Opioid Dependence
• Policy/Procedure No. 033 – Obtaining Informed Consent for Patient – Related Communications
• Patient Consent For The Release Of Confidential Information
• Policy/Procedure No. 034 – Patient Satisfaction Survey
• Center Of Excellence Patient Satisfaction Survey
• Opioid Use Disorder Diagnostic Checklist

Evaluation

• Policy/Procedure No. 035 – Quality Assurance Activities – Audit of Medical Record Documentation for Case Managers, Nurses, and Physician/Nurse Practitioners
• Medical Record Audit: Physician/Nurse Practitioner
• Medical Record Audit: Case Manager
• Medical Record Audit: Nurse
• Policy/Procedure No. 036 – Quality Assurance Activities: Staff Evaluation
• Performance Evaluation Form
• Staff Member Self-Assessment
• Policy/Procedure No. 037 – COE Outcomes
• Clinical Global Impressions Scale: Clinician
• Numeric Pain Distress Scale
• Policy/Procedure No. 038 – Data Flowsheet for Patients
• Data Flowsheet
• Policy/Procedure No. 039 – Patient Grievance

iv